SHANGHAI, March 5, 2019 /PRNewswire/ — The first “WuXi Healthcare Forum” opened at the St. Regis Shanghai Jing’an today, gathering together world-class scientists, alongside innovators, entrepreneurs, and investors. The forum attracts application of more than 5,000 industry leaders from 2,000 enterprises and organizations, spanning 20 countries, bring their collective insights to bare on the global challenges facing healthcare – exploring what breakthroughs have been achieved, the present realities and future possibilities.
The first WuXi Healthcare Forum opened in Shanghai
Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is facing unprecedented opportunities, but also, considerable challenges. The WuXi Healthcare Forum provides a platform to aggregate global expertise and is designed to promote international convergence and cooperation. Through the exchange of knowledge, experience and insights we will empower the continued growth of the healthcare ecosystem.
This two-day forum includes 20 sessions, with a central focus on “medicines for global impact” and “the new healthcare ecosystem”. Over 90 guest speakers will deliver cutting-edge insights on global cooperation in the healthcare industry in order to achieve the next disruptive innovation. The agenda addresses the establishment of an innovative ecosystem, the improvement of efficiency in new drug R&D, and the affordability and accessibility of healthcare products.
Alongside the world-class content, the forum features a special CEO roundtable program, which will showcase 200 innovative companies at the precipice of healthcare innovation.
In parallel to the Forum, partners including Huatai Securities, China Renaissance, Fangda Partners, Goldman Sachs, Morgan Stanley and Deloitte will hold several side events, where the participants can exchange their ideas on trends in healthcare development and popular investment strategies.
“We extend our warmest welcome to all our distinguished guests,” said Dr. Ge Li, Chairman of WuXi AppTec Group, “This is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past. It is my hope that more people will participate in contributing to the prosperity of the healthcare ecosystem, and we can take a step closer to realizing the shared dream of WuXi, and the whole industry that ‘every drug can be made, and every disease can be treated’.”
About WuXiAppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”
NEX China 2019 June 18-20 2019, SNIEC, Shanghai, China Organizer:UBM EMEA, CCCMHPIE Co-organizer:UBM Sinoexpo
SHANGHAI, March 4, 2019 /PRNewswire/ — In recent years, big health has risen as a national policy of China with the introduction of the “Healthy China 2030” Planning Outline, and China has specified the new positioning of the nutrition and health food industry. The market size of the Chinese health food industry is expected to reach about RMB403.6 billion in 2020. The active natural extracts have played a vital role in the process of acceleration of the entire nutrition and health food industry and the gradual maturity of the market, and the flourishing of the nutrition and health food industry has brought the steadily growing demand for the natural extract industry.
As the industry ushers in a new upsurge, NEX China will take place in Hall E4-E5 of Shanghai New International Expo Centre on June 18-20, 2019. The exhibition will be expanded to 20,000m2 this year and gather over 600 Chinese and overseas quality suppliers, with the industry development opportunities and resource superiority of China in the animal and plant extract area. Also to comply with the latest trend of big health, the organizer will hold plenty of match making and visiting group events for Chinese and overseas buyers of dietary supplements on site, to help enterprises forge ahead at the forefront of big health and build the future together.
2018 NEX China
Quality suppliers to be showcased, together with the leading-edge products and technologies
Moving ahead with the Chinese natural extract industry for 10 years, NEX China keeps an eye on the industry dynamics, continues to enrich the scope of exhibit, and guides numerous natural extract companies towards the international stage, which is recognized by top companies of the industry.
A large number of top companies of the industry will appear on the NEX China 2019 site, including Guilin Layn, Shaanxi Huike, Xi’an Yuensun, Acetar, Shaanxi Jiahe, Hunan Huacheng, Chenguang Biotech, Chongqing Joywin, Yuwang Pharmaceutical, and Angel Yeast. With their more diversified innovative products and technologies: the yeast beta-glucans extracted from yeast cell walls by Angel Yeast can significantly enhance immune activity, improve blood lipids and intestinal tract, and resist radiation, with the production and application technologies granted with many Chinese and overseas patents. The vegetarian soft capsule developed by Weihai Baihe is a capsule shell made from protein, and as the company has passed MUI Halal Certification, it can process the vegetarian soft capsules for pure oils, such as DHA algal oil capsules, flaxseed oil capsules and fish oil capsules. The phycocyanin extracted by Binmei Biotechnology from spirulina appears blue and has been recognized by the U.S. FDA, EU, and China’s GB2760 food additive list as natural food coloring, and it is also a nutritious protein itself and can also serve as a raw material for medicines, health products and cosmetics and as biochemical reagent. The joining of these industry leaders further proves that NEX China has become the platform of choice for quality enterprises of the industry to display brands, booster trades and make information exchanges.
2018 NEX China
Focusing on Healthy China and connecting the health food industry
In the context of the Healthy China, NEX China, the weather vane of the natural extract industry, has led Chinese natural extract companies to successfully connect the nutrition and health food industry through its commerce and trade strength in the industry. Many hi-level match making and grouping events for nutrition and health product buyers will be held on the 2019 exhibition site, wherein, the host will hold 2019 Health Product Buyer Matching Meeting jointly with the HNC 2019, to achieve maximum resource integration, promote all-win, and jointly help the big health industry achieve development, and transformation and upgrading. Furthermore, the host will also invite overseas buyers for cooperation together with industry-leading overseas media, so as to better satisfy the demand of Chinese enterprises to develop overseas markets and expand international business. There have been nearly 100 buyers from the Europe and North America who have registered and will talk face-to-face with exhibitors on site. Enterprises will access a direct and convenient channel to display innovative products and core technologies on the international stage, thereby rapidly establishing cooperation.
Alongside the matchmaking events, the China-US Pharmacopeia Forum hosted by the Chinese Pharmacopoeia Commission (ChP) and United States Pharmacopeia Convention (USP) and organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) will take place in China for the first time during the period of NEX China. The Forum will focus on the quality safety of natural plant products, provisions on heavy metal and pesticide residue, along with plant product international standards and trade regulations, and plans to invite experts from ChP, USP and officials from the National Medical Products Administration of China and the U.S. FDA to jointly discuss the development scenario for the plant extract and health industries. The host will also launch China-World Natural Ingredient Conference 2019, to gather authoritative experts from the Chinese and overseas governments, focus on customs code classification, international market trend, and global regulation changes relating to extracts, feel the pulse for industry development, and guide the development for enterprises. The topics of the Conference will include principles for customs classification of plant extracts, analysis of hot sale overseas varieties, influences of the U.S. FSVP on the export of the Chinese plant extracts, information sharing of innovative plant extract products, and overview of the export of plant extracts in the first half of 2019, etc.
The exhibition host: CCCMHPIE, an authoritative certification body for quality plant extracts in the industry, will also continue to introduce quality plant extract suppliers and quality products and launch awards of the innovative plant extract products of the year in China for the first time, to promote Chinese plant extract enterprises to build brand competitiveness. The certified exhibitors and products will be centrally displayed during the exhibition.
China-World Nature Ingredient Conference
Want to talk face to face with the industry giants, obtain the exclusive industry analysis report, and see the latest products and technologies? Register now to save RMB100 ticket fee. Visit the exhibition website www.cphi-china.cn/nex/en now to join the annual event of the natural extract industry!
-The 30-minute concluding episode airs during March 2-8
HONG KONG, March 4, 2019 /PRNewswire/ — Following the eight-month long series hosted by multiple Emmy-award winning chief medical correspondent Dr. Sanjay Gupta, CNN is airing a 30-minute concluding episode of ‘Live Longer’ this month, which continues to highlight aspects of our lives that impacts longevity, ranging from factors we can control – like diet, exercise, and smoking to the factors we can’t – such as the environment and our own genetics.
CNN’s ‘Live Longer’ explores the latest science, technology and research for a healthier and longer lifespan
Launched in July 2018, CNN’s ‘Live Longer’ explored how the latest science, technology and research can increase life expectancy. Throughout these eight months, CNN traveled to different countries including Ireland, Hong Kong, and Sweden to explore how certain lifestyle changes can positively impact lifespan, and lead to a longer and better life.
In the special 30-minute final episode, CNN travels from the crystal blue waters of the Caribbean, to the harbor of vibrant Hong Kong, with 49-year-old Chris Hay, CEO of a global company. On airplanes as much as he is at home, the busy lifestyle of this world-traveling executive presents a challenge many people can relate to. In his conversation with Dr. Sanjay Gupta, Chris shared his reflection after the tragic wake-up call about his health – a sudden heart attack few years ago caused by 80-percent blockage in his left artery – and conveyed his message to help us all live Longer.
CNN also talks to Dr. Christopher Murray from University of Washington, who specializes in the data behind our health and longevity, to gain insight into lifespan trends over the next two decades, as we try to improve not just the length of our lives, but the quality of those years.
‘Live Longer’ is produced by CNN Vision, the global creative production powerhouse of CNN International, which brings the world’s breath-taking diversity into cinematic focus, telling stories that inspire audiences around the world.
Saturday, 2nd March at 2130 HKT Sunday, 3rd March at 0030 HKT Monday, 4th March at 0930 HKT and 1730 HKT Thursday, 7th March at 1730 HKT Friday, 8th March at 0130 HKT
About CNN International
CNN’s portfolio of news and information services is available in seven different languages across all major TV, digital and mobile platforms reaching more than 475 million households around the globe. CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America and has a US presence which includes CNNgo. CNN Digital is a leading network for online news, mobile news and social media. CNN is at the forefront of digital innovation and continues to invest heavily in expanding its digital global footprint, with a suite of award-winning digital properties and a range of strategic content partnerships, commercialised through a strong data-driven understanding of audience behaviours. Over the years CNN has won multiple prestigious awards around the world for its journalism. Around 1,000 hours of long-form series, documentaries and specials are produced every year by CNNI’s non-news programming division, CNN Vision. CNN has 36 editorial offices and more than 1,100 affiliates worldwide through CNN Newsource. CNN International is part of Turner, a WarnerMedia company.
-New brand reflects commitment to Science, Results, Trust
WAYLAND, Massachusetts, March 2, 2019 /PRNewswire/ — Syneron-Candela, a leading global medical aesthetic device company, announced today that it has rebranded the company to Candela and will be unveiling new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting in Washington D.C, between March 1-5, 2019. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth as a unified single entity.
Established in 1970, Candela, has a long history of technological innovation bringing to market best in class medical aesthetic energy-based devices. “Re-launching the company as Candela and aligning around its brand pillars of Science, Results and Trust, reflects our commitment to Candela’s guiding principles of safety, efficacy and reliability. It also reflects our commitment to strengthening the longstanding partnerships of trust Candela has established with physicians, their practices and the patients they treat,” says Geoffrey Crouse, Chief Executive Officer of Candela. Candela’s new brand identity will go live today with the launch of its new corporate website www.candelamedical.com, new marketing materials, print, digital and social campaigns. New patient, physician and practice focused assets will continue to be rolled out over the course of the year.
“Scientific rigor, clinical outcomes and building trusting partnerships with physicians are the same values that established Candela’s historic leadership over the years. The combination of Candela’s new management, innovation of products such as the Vbeam Prima system coupled with Candela’s values, strongly positions the company for continued growth while making them an even more trusted partner to medical aesthetic practices globally,” says Eric Bernstein, MD, an Ardmore, Pennsylvania based dermatologist who is also chairperson of Candela’s Medical Advisory Board.
In addition to unveiling its new visual brand identity, Candela’s products and technologies highlighting clinical outcomes will be presented during 18 clinical presentations and educational courses at the AAD. Candela will also be showcasing its newest products–the Vbeam® Prima and Nordlys systems. The Vbeam Prima device is an advanced 595 nm pulse dye laser (PDL). With the addition of a 1064 nm wavelength and a number of other new user focused features, the Vbeam Prima device is able to effectively treat a broad range of skin conditions, including: rosacea, port wine stains, acne, facial, leg and spider veins, scars, benign pigmented lesions and wrinkles, warts, stretch marks and photo aging.
The Nordlys device is a multi-application, multi-technology IPL and Nd:YAG platform for vascular and pigmented lesions, as well as hair removal. The Nordlys system also offers a fractionated 1550 nm handpiece for skin resurfacing. Both devices as part of the entire portfolio of Candela products will be on display at the Candela exhibit (#2137) at the 2019 AAD. For more information about the Vbeam Prima and Nordlys devices and the Candela portfolio, please visit www.candelamedical.com.
About Candela® Candela is a leading US based global medical aesthetic device company with headquarters in Wayland, Massachusetts. The company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, tattoo removal, women’s health treatments, facial resurfacing, traumatic and surgical scar treatments, body contouring, improving the skin’s appearance through the treatment of benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Candela has a wide portfolio of trusted, leading products, including Vbeam®, the Gentle Family®, CO2RE®, CO2RE Intima®, Profound®, elōs Plus®, PicoWay®, UltraShape®, VelaShape®, IPL and other laser-based platforms. Acquired by Apax Partners in July 2017, the Company has an expansive global footprint and markets, services and supports its products in 86 countries. It has offices in the United States, Australia, Canada, mainlandChina, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom and many international distributors.
LAUSANNE, Switzerland, March 1, 2019 /PRNewswire/ — Firstrandomized clinical trialcomparing the efficacy andsafety of combineddoxycycline 40 mg modified release (DMR) and ivermectin 1% cream(IVM),versus ivermectin 1% cream plusplaceboin adults with severepapulopustularrosacea,revealsmore than doublethe numberof patientsreach‘clear‘(100% lesion clearance) at 12 weeks
Today, Galderma shares the results of its ANSWER study, which highlights a superior reduction of inflammatory lesions with combination doxycycline 40 mg modified release capsules (DMR) and ivermectin 1% cream (IVM), compared to IVM plus placebo, in adults with severe papulopustular rosacea (IGA 4*) at 12 weeks.
Clinicians often use a combination of topical and oral therapies for the treatment of rosacea. A previous study confirmed the increased benefits of combination therapy.[1] More recently, once daily IVM has been shown to be more effective than twice daily metronidazole 0.75%.[2] The ANSWER study is the first to evaluate the combination of IVM and DMR, which is the only approved oral treatment for inflammatory rosacea lesions.[3]
According to the results, the combination treatment was associated with 2.5 times more patients achieving 100% lesion clearance already at 12 weeks compared with IVM plus placebo (17.8% vs. 7.2%). DMR and IVM also worked significantly faster than IVM plus placebo, with significant differences seen as early as week 4. The safety profile of both treatment arms was generally well tolerated with no significant differences between the arms. The data is revealed as a poster at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C., USA.[4]
“ANSWERis a significant step forward for people suffering with severe rosacea, andforcliniciansin this field. The data shows combination therapy with IVM + DMR was a safe and more efficacious option with afaster onset of action compared to IVMalone,“ says Dr James Del Rosso, DO of JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada, who is presenting the data at AAD.
“Reaching clear is a tremendous achievement for those living with this chronic, visible disease.Through combination (DMR + IVM) treatmentmore peoplewillhave the opportunity toreach clear and be relieved of thephysical,emotional and psychological burden of this disease.“
Results showed a consistent outcome in doubling the number of patients achieving ‘clear’ (IGA 0) which is defined as 100% clearance in inflammatory lesions and erythema (redness) at 12 weeks using combination therapy (11.9% vs 5.1%) in this severe population.
In addition, three quarters of patients in both treatment groups saw a reduction in burning and stinging sensations by week 12, with 73.3% and 75.4% of patients reporting complete elimination of these symptoms on combination therapy and monotherapy, respectively. Both treatment arms also experienced a substantial increase in the proportion of patients without flushing episodes (-47.2% IVM+DMR vs -41.9% IVM+PBO) and a significant improvement in DLQI** (quality of life).
“The ANSWER results demonstrate the optimized clinical outcome of associating these two treatmentsin patients with severerosacea,both known for theirefficacy andsafety profile.Ivermectin again showed efficacyandthecombinationwithmodified releasedoxycyclinehas significantly increased the number of patients achieving 100% lesion reduction,without compromising the safety profile“ says Kamel Chaouche, Head of Global Medical Affairs Rx SIG, Galderma Nestle Skin Health.
“Galderma has along-standingcommitment toskin healthandwe knowthatthe impact dermatological conditions have on peopleismore than skin-deep, regardless of severity. ANSWERprovides us with importantnew evidencewhichsupportsour missionto help patientswithrosaceatoreach clear.“
* The success of rosacea treatment is usually defined as a score of 1 (‘almost clear‘) or 0 (‘clear‘) on the 5-point Investigator Global Assessment (IGA) scale. Several studies have shown that patients who achieve‘clear‘(IGA 0), a complete reduction in symptoms, experience an extended time to relapse and an improved quality of life compared with patients who are‘almost clear‘(IGA 1)[5]
**DLQI is the most well-known quality-of-life index in dermatology[6]
Del Rosso J et al. Combined doxycycline 40 mg modified release capsules plus ivermectin 1% cream therapy for severe rosacea. 3 March 2019. Poster presented at 2019 AAD Annual Meeting, Washington, D.C., USA. Poster 10628
Webster G et al. J Dermatolog Treat. 2017;28(5):469-474
Shikiar R, et al. Health and Quality of Life Outcomes 2005;3:36
About Rosacea
Rosacea is a common inflammatory skin disease that presents variable clinical characteristics, of which the most common are flushing, permanent erythema, and inflammatory lesions. It mainly affects the central areas of the face, such as the cheeks and nose. The disease can affect both adult men and women, usually after the age of 30. Additionally, symptoms such as stinging, burning and increased sensitivity of the skin are common. The eyes are often affected, and might present as red, dry or itchy.
Although the cause of the disease is still under debate, various trigger factors are known, including spicy foods, alcohol, emotional stress, sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, can also be found in the skin in an elevated quantity in people with rosacea.
Rosacea may worsen over time if left untreated. People that suspect they suffer from rosacea should visit their dermatologist or healthcare provider for diagnosis and discuss what treatment is right for them. Because rosacea is a highly visible disease, it is known to cause embarrassment and anxiety in some patients, which in turn may cause frustration and have a negative impact on their social life.
About ANSWER
ANSWER is a multicenter (US, EU, CAN), randomized, vehicle-controlled, investigator-blinded, parallel-group, comparison study treating patients with severe rosacea (IGA 4) with concomitant use of topical ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release (DMR) capsules. The aim of the study was to evaluate if IVM + DMR association is more efficient than IVM + placebo alone. Patients received either IVM + DMR (n= 135) or IVM + placebo once daily for 12 weeks (n= 138). Subjects were ≥18 years, with >20 to max. 70 inflammatory lesions (papules and pustules) on the face.
About Galderma
Galderma, Nestle Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit http://www.galderma.com
Galderma media relations contact
Sebastien Cros Global Communications +41-21-642-76-94 media@galderma.com
SHANGHAI, March 1, 2019 /PRNewswire/ — CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA).
“At the American Society of Hematology meeting in December 2018, our collaborator, Dr. Songfu Jiang presented encouraging safety and efficacy data in patients with rrMM who received CT053 BCMA–CAR–T cells. The IND clearance of BCMA-CAR-T cells by China’s NMPA is of great significance to CARsgen,” said Dr. Zonghai Li, founder, CEO and CSO of CARsgen. “According to JAMA Oncology, in 2016, there were about 130,000 cases of myeloma, which means from 1990 to 2016, incident cases of myeloma increased by 126% globally[1] and despite the development of novel therapies, multiple myeloma remains incurable and new treatment options are needed. As part of the CT053 development plan, we also intend to submit an IND application for BCMA-CAR-T cells to the U.S. FDA in 2019. Our goal is to continue the development of novel, safe and effective immunotherapies. This is our long-standing commitment to cancer patients worldwide.”
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development and commercialization of CAR-T therapeutics for unmet medical need. The company has collaborated with top hospitals in China to launch several First-in-Human studies such as CAR-GPC3-T for hepatocellular carcinoma and squamous lung cancer, CAR-EGFR/EGFRvIII-T for glioblastoma multiforme and CAR-Claudin18.2-T for gastric and pancreatic cancer.
SAN MATEO, California, March 1, 2019 /PRNewswire/ — Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, today announced that it has changed its name to Rakuten Medical, Inc. This name more closely reflects the company’s corporate purpose of creating a global biotechnology company integrating research and development with commercial operations in order to develop therapeutics that improve cancer patient outcomes.
“We are aiming to deliver PIT platform to as many cancer patients and as early as possible worldwide. Our new name that becomes effective today, Rakuten Medical, better aligns with our goal of developing a global brand that resonates within the pharmaceutical and medical device industries,” said Mickey Mikitani, chairman and CEO of Rakuten Medical. “Despite our name change, our mission of ‘Conquering cancer, For life’ will not change. We are stronger today than ever before as we continue building the organization necessary to conquer cancer by developing innovative cancer treatments.”
Rakuten Medical, Inc. is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy (PIT). We aim to discover, develop and commercialize therapies to treat cancer patients worldwide and fulfill our mission to conquer cancer. The corporate headquarters is in San Mateo, California, U.S.
About Photoimmunotherapy (PIT)
Since 2013, Rakuten Medical has been developing new anticancer therapies based on the Photoimmunotherapy platform.
Photoimmunotherapy combines key advantages of antibody mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Medical is building R&D and Commercial capabilities by studying Photoimmunotherapy platform.
About ASP-1929 Photoimmunotherapy
ASP-1929, a conjugate of cetuximab and IRDye 700DX®, targets epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck squamous cell carcinomas, esophagus, lung, colon, pancreas and other cancers. This first-in-class therapy targets cancer cells, after which the compound is locally activated with red light using a proprietary investigational laser and fiber optics. The local activation of the tumor-selective conjugate targets the tumor but not surrounding normal tissues and structures. ASP-1929 received Fast Track designation by the U. S. Food and Drug Administration for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC).
Interim results of a Phase 1/2 trial in patients with HNSCC showed a clinically meaningful improvement in the objective response rate, and potential improvements in progression free survival and overall survival when compared to historical data for the standard of care treatments currently available to this patient population. Top line results of the ASP-1929 Phase 1/2 trial are expected in the first quarter of 2019.
ASP-1929 is an investigational compound that is not approved for any use in any country.
Forward Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Rakuten Medical actual results, plans and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to Rakuten Medical’s products such as ASP-1929. Such approvals or success may not be obtained or achieved on a timely basis or at all. Forward-looking statements include statements relating to the potential benefits, safety and efficacy of ASP-1929, and the status of current regulatory filings. These statements may be identified by words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “intends,” “potential,” “may,” “suggest, “plan,” “strategy,” “should,” “will” and all other similar expressions, and are based on our current beliefs. In addition, this press release includes qualifying terms such as “significant,” “remarkable,” “extraordinary,” etc. that describe opinions on clinical data. Ongoing clinical studies involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in regulatory approval or commercialization of ASP-1929 which may be impacted by, among other things, problems with the manufacturing process for ASP-1929, the occurrence of adverse safety events, failure to demonstrate therapeutic benefit, and the other risks and uncertainties, both reasonable and unreasonable. We undertake no obligation to publicly update this or any other forward-looking statement, whether because of new information, future developments or events, changes in assumptions, changes in the factors affecting forward-looking statements or otherwise except to the extent required by applicable laws. If Rakuten Medical updates one or more forward-looking statement(s), no inference should be drawn that we will make additional updates with respect to that, those or other forward-looking statements.
SHANGHAI, March 1, 2019 /PRNewswire/ — Sanofi announced that Pius S. Hornstein, PhD, has been appointed the new General Manager China, China & Emerging Markets Global Business Unit (GBU) of Sanofi and Country Chair of Sanofi China, effective today. Based in Shanghai, he reports directly to Olivier Charmeil, Executive Vice President of Sanofi, Head of China & Emerging Markets, and member of the Sanofi Executive Committee.
Jean-Christophe Pointeau, who held the role over the last four years and has successfully brought Sanofi China to its strong level today, has been appointed Europe Region Head, Sanofi Genzyme. Since January, Pointeau and Hornstein have been working together to ensure a smooth and successful transition given the importance of China to the Sanofi Group.
“China is the second largest affiliate of Sanofi, with a 12,7% sales growth in 2018. I firmly believe that Pius Hornstein will drive Sanofi China from great to greater, building on our longstanding presence in the country and accelerating our innovation path,” said Olivier Charmeil. “On January 1, we have officially launched our Sanofi China & Emerging Markets Global Business Unit. It is focused on the unique characteristics and growth opportunities in emerging markets. Sanofi will leverage emerging markets as a key growth engine by further boosting its investment in these regions, especially in China.”
“Leading the China affiliate is a great honor and responsibility, as it represents the second-largest market for Sanofi,” said Hornstein. “With the rapid changes in the environment, my priority will be to bring innovation to the market faster and to focus on the development of our rich talent pool in China.”
“We will continue to deliver on Sanofi’s commitment of ‘in China, for China,’ adhere to the highest standard of ethics, and help Chinese patients and people to benefit from more innovative drugs and vaccines, as we contribute to the Healthy China 2030 initiative,” he added. “We shall never stop pursuing growth and a greater leadership position. Together with all employees in China, I am confident and enthusiastic about driving our growth momentum and fostering Sanofi’s position as one of the leading healthcare companies in China, building on our longstanding commitment, innovation and partnership approach.”
Hornstein was the General Manager and Country Chair of Sanofi Brazil for the last four years. He joined Sanofi in 1998 as a product manager, and held a variety of key positions in marketing, sales management and other global strategic areas. He led the global team for the anticoagulant that is part of the World Health Organization list of essential medicines. He has a master’s degree in pharmacy and a PhD degree in medical research from the University of Basel in Switzerland.
As one of the first multinational pharmaceutical companies to enter China, Sanofi is a leader in chronic disease management and vaccines, and a pioneer in rare diseases. Sanofi has introduced more than 40 high-quality innovative drugs and vaccine products to the China market, with its diversified therapies covering seven of China’s top 10 life-threatening diseases. Sanofi China will remain committed to accelerating innovation, and is expected to launch 16 new products and indications in China by 2025.
Pius S. Hornstein, PhD
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
About Sanofi China
In 1982, Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. Sanofi’s China headquarters in Shanghai are supported by 11 offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi. Sanofi has around 9,600 employees in China.
Sanofi has three manufacturing facilities in China to meet the increasing demand of the domestic market. These plants are located in Beijing, Hangzhou and Shenzhen.
Sanofi operates the China R&D Center and Asia Pacific R&D Hub in Shanghai, Global R&D Operations in Chengdu, and Global Research Institute in Suzhou. Sanofi’s R&D focuses on unmet medical needs, such as oncology, immunology, and metabolic diseases in China and the rest of the world.
For more information, please visit www.sanofi.cn or subscribe to the Sanofi China official WeChat account: SanofiChina.
Pius S. Hornstein, PhD
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) announced today that the Japan Patent Office granted the patent for TRIANNI’s leading technology, The Trianni Mouse™. The Trianni Mouse is a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies.
“This patent is an important addition to our intellectual property portfolio, providing protection to our proprietary technology in Japan’s diverse market,” remarked Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. “The issuance recognizes TRIANNI’s unique approach of using chemically synthesized large DNA fragments with sequences non-existent in nature over traditional methods. Designed in silico, these fragments are modified versions of the mouse immunoglobulin loci, with human exons embedded in mouse control regions and intergenic DNA.”
About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI’s lead technology, The Trianni Mouse™, is a simple-to-use platform that enables efficient generation of fully-human monoclonal antibodies with no developability issues. The transgenic platform leverages a novel approach to design, which was made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA, USA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.
Contact- Trianni, Inc. Mandy Boyd Director of Marketing 1.415.231.0256 [o] 1.866.674.9314 mandy.boyd@trianni.com
In a human-intervention trial published recently in the journal Nutrients, researchers at the USDA, ARS, Beltsville Human Nutrition Research Center, looked at the available energy content in cashew nuts[1].
Eighteen healthy volunteers were recruited to participate in this 9-week study. Participants consumed a controlled base diet supplemented with cashew nuts (42 g/day) during one treatment period of 4 weeks, or a controlled base diet with no-cashew supplementation during another treatment period of 4 weeks. Diet samples from the study, as well as feces and urine from eighteen volunteers, were collected during the final week of each intervention phase and analyzed for protein, fat and energy content. From these, researchers were able to determine the actual digestible energy content of cashews.
Study results showed that the available energy (calorie) content of cashews is 16% lower than that which is typically stated on current food labels and databases in the United States, including the National Nutrient Database for Standard Reference. These must be corrected in order to provide consumers with accurate energy values. Whereas the current reported energy value is 163 kcal/serving, USDA researchers found that the metabolizable energy content of a 28 g (1 oz) serving of cashews is 137 kcal.
Meanwhile, another recent study published in The American Journal of Clinical Nutrition concluded that 42 g/day of cashews does not increase LDL “bad” cholesterol levels[2]. The study also observed that adding 42 g of cashews every day to a typical Western diet may help reduce the enzyme PCSK9, and lower PCSK9 concentrations are associated with the removal of LDL “bad” cholesterol from the blood.
This study was supported by the Global Cashew Council and the INC International Nut and Dried Fruit Council.
[1]. Baer, D., & Novotny, J. (2019). Metabolizable Energy from Cashew Nuts is Less than that Predicted by Atwater Factors. Nutrients, 11(1), 33.
[2]. Baer, D. J., & Novotny, J. A. (2019). Consumption of cashew nuts does not influence blood lipids or other markers of cardiovascular disease in humans: a randomized controlled trial. The American Journal of Clinical Nutrition, 109(2), 269-275.
